WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines
In November, ICMRA and the World Health Organization (WHO) committed to working together to ensure that patients have access to safe and effective medicines against COVID-19 as early as possible, while the existing rigorous scientific standards for the evaluation and safety monitoring of treatments and vaccines are maintained at all times.
WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines (6 November 2020)
In their joint statement, ICMRA members and WHO:
- reiterate that therapeutics and vaccines against COVID-19 can only be rapidly approved if applications are supported by robust and sound scientific evidence that allows medicine regulators to conclude on a positive benefit-risk balance for these products;
- pledge to take concrete actions to ensure equitable access to safe, effective and quality-assured medicines for the treatment or prevention of COVID-19 around the world.
Statement in other languages
- Arabic - بيان مشترك من منظمة الصحة العالمية (WHO) والتحالف الدولي للجهات الرقابية على الأدوية (ICMRA) حول الحاجة إلى التنسيق بين الهيئات الرقابية العالمية بشأن الأدوية واللقاحات الخاصة بفيروس كورونا COVID-19
- Chinese Mandarin - 世界卫生组织—药物管制当局国际联盟关于需要改进2019冠状病毒病(COVID-19)药物和疫苗全球监管协调的联合声明
- French - Déclaration commune de l’OMS et de l’ICMRA sur la nécessité d’une meilleure harmonisation réglementaire mondiale sur les médicaments et les vaccins contre la COVID-19
- Japanese - COVID-19医薬品及びワクチンに関する国際規制協力の必要性に関するWHO-ICMRA共同ステートメント
- Korean - 코로나19 의약품 및 백신의 글로벌 규제 조화 개선 필요성에 관한 WHO-ICMRA 공동 성명
- Russian - Совместное заявление ВОЗ и ICMRA о необходимости повышения согласованности режимов регулирования в отношении лекарственных средств и вакцин против COVID-19 во всем мире
- Spanish - Declaración conjunta ICMRA-OMS sobre la necesidad de mejorar el alineamiento global a nivel regulatorio de los medicamentos y vacunas contra la COVID-19